Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3017418 | 1.00 | MAPT (0.54) | MAPTPKMSLC6A3SLC6A4SLC6A2 | |
| SCHEMBL14642003 | 1.00 | MAPT (0.54) | MAPTPKMSLC6A3SLC6A4SLC6A2 | |
| SCHEMBL13209102 | 1.00 | MAPT (0.54) | MAPTPKMSLC6A3SLC6A4SLC6A2 | |
| SCHEMBL5905307 | 0.89 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL5905617 | 0.89 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL18244752 | 0.89 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL16033453 | 0.87 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL16033454 | 0.87 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL16070070 | 0.87 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL14610892 | 0.82 | MC4R (0.46) | MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391615-B1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-01-16 | — | — | EP | disclosed |
| US-8324248-B2 | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-12-04 | — | — | US | disclosed |
| CN-102282139-A | Piperidine derivatives as nk3 receptor antagonists | — | 2011-12-14 | — | — | CN | disclosed |
| EP-2391615-A1 | Piperidine derivatives as nk3 receptor antagonists | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| US-20100197697-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | US | disclosed |
| WO-2010086259-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197697-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | OPRK1, OPRM1, OPRL1 | MAPT 292/4885PKM 584/4885SLC6A3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.